Pfizer's Lorbrena breaks into front-line ALK lung cancer, jostling with Novartis, Roche and Takeda

Pfizer’s Lorbrena has finally broken into front-line non-small cell lung cancer, where Novartis, Roche and Takeda are already jockeying for a niche market.

The FDA expanded Lorbrena’s use into newly diagnosed patients with ALK-positive NSCLC, Pfizer said Wednesday. With that front-line nod, the agency converted Lorbrena's conditional green light for previously treated cases into a full approval.